share_log

Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Lowers Price Target to $28

Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Lowers Price Target to $28

Chardan Capital維持對EyePoint製藥的買入,將目標股價下調至28美元
Benzinga ·  05/07 08:51

Chardan Capital analyst Daniil Gataulin maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and lowers the price target from $39 to $28.

查爾丹資本分析師丹尼爾·加陶林維持EyePoint Pharmicals(納斯達克股票代碼:EYPT)的買入並將目標股價從39美元下調至28美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論